Laura Dill Morton2020-11-11T22:13:42+00:00

Laura Dill Morton

Laura Dill Morton received her D.V.M. degree from the Ohio State University, graduate pathology training from Texas A&M University and the University of Illinois, and a Ph.D. in Pathobiology from the University of Illinois.  She is certified by the American College of Veterinary Pathologists in anatomical pathology and is a Diplomate of the American Board of Toxicology.  Currently, she is a Senior Consultant for Aclairo Pharmaceutical Development Group, a subsidiary of Experimental Pathology Laboratories, Inc.  Prior to her position with Aclairo, she was an Executive Director in Preclinical Safety at Novartis, Inc., in Cambridge, MA where she was the preclinical therapeutic area lead for cardiovascular and metabolic products. Prior to Novartis, Dr. Morton was employed at Pfizer Inc. in Groton where she led preclinical safety participation in due diligence and acquisitions. She has experience across a range of therapeutic modalities including small and large molecule drugs, gene therapy, cell therapy, gene editing, and therapeutic vaccines and has worked at all stages of drug development from discovery through registration. Dr. Morton has worked on drugs for indications in oncology, cardiovascular, metabolic, ophthalmology, neurodegenerative and infectious diseases. She has extensive experience in interacting successfully with CBER as well as CDER.  Her consulting practice is currently focused on providing strategic advice and developing regulatory communications for sponsors developing advanced therapy medicinal therapeutics that will be submitted through FDA CBER or EMA Committee for Advanced Therapies (CAT)